Tsoutsou Pelagia

Prof. Pelagia Tsoutsou

Head of Radiation Oncology Department



Born in Greece, I studied Medicine (1993-1999) and obtained my MD-PhD (2004) in the University of Thessaly, Faculty of Medicine. I was trained in Radiation Oncology in Athens, Greece and Lille, France, before obtaining my postgraduate diploma in Radiation Oncology in 2006 and occupying a Senior Lecturer position and medical staff in the Democritus University of Thrace and Univeristy Hospital of Hospital of Alexandroupolis from then on and until 2011. Cheffe de Clinique at CHUV from 2011-2013, then Médecin Adjointe in the Valais Hospital, I then obtained the position of Head of Radiation Oncology Department in Neuchâtel Hospital (2015-2018) as well as Head of The Oncology Division ai (2018-2019). Head of the Radiation Oncology Department in Geneva University Hospital since 2019, I reorganized the Department so that quality care through multidisciplinarity can be made available to all cancer patients in the Geneva canton. My research focuses on breast cancer, improvement of the therapeutic ratio of radiotherapy and innovative radiotherapy, such as FLASH.

My main research interests concern radiation interaction with systemic treatments (radioprotectors and radiosensitizers, as well as immunotherapy). Innovative radiotherapy (FLASH) clinical transfer is another axis of efforts to improve the therapeutic ratio in which I focus. With a clinical and research expertise in breast cancer, I try to bring preclinical innovation to clinical practice, by focusing on new radiotherapy roles in this setting, as well as the systemic effects of a local treatment, radiotherapy. Notably, in terms of improving the therapeutic ratio of radiotherapy, my works include the evaluation in clinical research of amifostine, a radioprotector, as well as the preclinical evaluation of radiosensitizers, such as TAT-RasGAP(317-326) et Debio 1143, the latter being currently evaluated in a phase III setting. Working further within this clinical/preclinical tandem with the CHUV Radiobiology laboratory, I explored cardiotoxicity of radiotherapy and drugs in breast cancer, and participated into FLASH radiotherapy development, focused on its clinical transfer.

Breast cancer heterogeneity and its introduction into radiotherapy practice, clinical research with innovative roles for radiotherapy (immunostimulation) in selected populations of breast cancer, as well as systemic effects of breast cancer radiotherapy represent my specific research interests in my discipline. My core expertise concerns breast cancer radiotherapy, association of radiotherapy and systemic agents, immunostimulatory as well as FLASH radiotherapy.


  • Weber WP, Shaw J, Pusic A, Wyld L, Morrow M, King T, Mátrai Z, Heil J, Fitzal F, Potter S, Rubio IT, Cardoso MJ, Gentilini OD, Galimberti V, Sacchini V, Rutgers EJT, Benson J, Allweis TM, Haug M, Paulinelli RR, Kovacs T, Harder Y, Gulluoglu BM, Gonzalez E, Faridi A, Elder E, Dubsky P, Blohmer JU, Bjelic-Radisic V, Barry M, Hay SD, Bowles K, French J, Reitsamer R, Koller R, Schrenk P, Kauer-Dorner D, Biazus J, Brenelli F, Letzkus J, Saccilotto R, Joukainen S, Kauhanen S, Karhunen-Enckell U, Hoffmann J, Kneser U, Kühn T, Kontos M, Tampaki EC, Carmon M, Hadar T, Catanuto G, Garcia-Etienne CA, Koppert L, Gouveia PF, Lagergren J, Svensjö T, Maggi N, Kappos EA, Schwab FD, Castrezana L, Steffens D, Krol J, Tausch C, Günthert A, Knauer M, Katapodi MC, Bucher S, Hauser N, Kurzeder C, Mucklow R, Tsoutsou PG, Sezer A, Çakmak GK, Karanlik H, Fairbrother P, Romics L, Montagna G, Urban C, Walker M, Formenti SC, Gruber G, Zimmermann F, Zwahlen DR, Kuemmel S, El-Tamer M, Vrancken Peeters MJ, Kaidar-Person O, Gnant M, Poortmans P, de Boniface J. Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy.Breast. 2022 Jun;63:123-139. doi: 10.1016/j.breast.2022.03.008. Epub 2022 Mar 18.PMID: 35366506 
  • Tsoutsou P, Annibaldi A, Viertl D, Ollivier J, Buchegger F, Vozenin MC, Bourhis J, Widmann C, Matzinger O. TAT-RasGAP(317-326) Enhances Radiosensitivity  of Human Carcinoma Cell Lines In Vitro and In Vivo through Promotion of Delayed Mitotic Cell Death. Radiat Res. 2017;187(5):562-569.
  • Matzinger O, Viertl D, Tsoutsou P, Kadi L, Rigotti S, Zanna C, Wiedemann N, Vozenin MC, Vuagniaux G, Bourhis J. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma. Radiother Oncol. 2015 ;116(3):495-503


 Link to  full publication list here